What type of monitoring should be performed during treatment with Clolar?
Because of the pre-existing immunocompromised condition of most patients, and the rapid reduction in peripheral leukemia cells and the prolonged neutropenia that can result from treatment with Clolar, nurses should closely evaluate and monitor patients for signs and symptoms of infection, tumor lysis syndrome, and cytokine release (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that could develop into SIRS/capillary leak syndrome, and organ dysfunction. Careful hematologic monitoring during therapy is important. Hepatic and renal function should be assessed prior to and during treatment with Clolar, as the liver is a target organ for Clolar toxicity and the kidneys are the predominant mode of Clolar excretion. The respiratory status and blood pressure should be closely monitored during infusion of Clolar.
